0173-0892 : Nucala 100 mg/ml Subcutaneous Injection, Solution
| NDC: | 0173-0892 |
| Labeler: | Glaxosmithkline LLC |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Nucala |
| Dosage Form: | Subcutaneous Injection, Solution |
| Application #: | BLA761122 |
| Rev. Date: |
NDC Package Codes:
- 0173-0892-01: 1 SYRINGE IN 1 CARTON (0173‑0892‑01) > 1 ML IN 1 SYRINGE
- 0173-0892-42: 1 SYRINGE IN 1 CARTON (0173‑0892‑42) > 1 ML IN 1 SYRINGE
- 0173-0892-61: 1 SYRINGE IN 1 CARTON (0173‑0892‑61) > 1 ML IN 1 SYRINGE
- 0173-0892-63: 1 SYRINGE IN 1 CARTON (0173‑0892‑63) > 1 ML IN 1 SYRINGE
Active Ingredients:
- Mepolizumab
Dosage Strength:
- 100 mg/mL
Pharmaceutical Classes:
- Interleukin-5 Antagonist [EPC]
- Interleukin-5 Antagonists [MoA]
Related Products:
Based on records with the same trade name.- 0173-0881 Nucala 100 mg/ml Subcutaneous Injection, Powder, for Solution by Glaxosmithkline LLC
- 0173-0904 Nucala 40 mg/.4ml Subcutaneous Injection, Solution by Glaxosmithkline LLC
- 12064-018 Nucala 100 mg/ml Subcutaneous Injection, Powder, for Solution by Glaxosmithkline Manufacturing Spa
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 0173-0889Next: 0173-0893 >
Related Discussions:
can mepolizumab be a cause for hypercalcemia?
I have a patient on a trial with it, and now she has hypercalcemia. Could this be due to the med or do I have to investi... 1 reply
I have a patient on a trial with it, and now she has hypercalcemia. Could this be due to the med or do I have to investi... 1 reply
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.